FDA clears Medtronics stent for use in iliac arteries

Justine Varieur Cadet | | Health Imaging | Screening
Medtronic has received FDA approval for the Complete SE vascular stent system to be used for the treatment of peripheral arterial disease in the iliac arteries.

The Complete SE vascular stent system features a dual-deployment delivery system with a triaxial design, according to the Minneapolis-based company. The new delivery system is made up of an inner shaft, a retractable sheath and a stabilizing sheath.

Robert Molnar, MD, of Michigan Vascular Research Center in Flint, and William Gray, MD, director of endovascular intervention at New York-Presbyterian Hospital/Columbia University Medical Center in New York City, led the study (as co-principal investigators) that contributed to this approval.

Justine Varieur Cadet

Related Content

AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.